PHILADELPHIA, Oct. 13, 2011 /PRNewswire/ — Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing the Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude® SkinPrep System for transdermal drug delivery, today announced that it is initiating a clinical study of its Symphony tCGM System in patients with Type 1 and Type 2 diabetes. The company expects to complete and announce the results of the study in the fourth quarter, and plans to subsequently begin a separate study in critical care patients…

http://www.prnewswire.com/news-releases/echo-therapeutics-initiates-clinical-trial-of-its-symphony-tcgm-system-in-patients-with-type-1-and-type-2-diabetes-131776963.html